Q3 EPS Forecast for USANA Health Sciences Raised by Analyst

USANA Health Sciences, Inc. (NYSE:USNA) – Equities researchers at Sidoti boosted their Q3 2026 earnings per share (EPS) estimates for shares of USANA Health Sciences in a report issued on Thursday, August 6th. Sidoti analyst A. Lebiedzinski now expects that the company will post earnings per share of $0.11 for the quarter, up from their previous forecast of $0.09. The consensus estimate for USANA Health Sciences’ current full-year earnings is $0.76 per share. Sidoti also issued estimates for USANA Health Sciences’ Q1 2027 earnings at $0.34 EPS and Q2 2027 earnings at $0.46 EPS.

A number of other equities research analysts have also recently issued reports on the company. Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Finally, Zacks Research cut USANA Health Sciences from a “hold” rating to a “strong sell” rating in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

USANA Health Sciences Stock Down 4.1%

USANA Health Sciences stock opened at $13.76 on Monday. The company’s 50-day moving average price is $20.24 and its two-hundred day moving average price is $19.53. The stock has a market cap of $253.94 million, a P/E ratio of -11.37, a P/E/G ratio of 1.57 and a beta of 0.73. USANA Health Sciences has a twelve month low of $13.73 and a twelve month high of $32.32.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The company had revenue of $223.27 million during the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc increased its holdings in USANA Health Sciences by 1,472.3% in the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock valued at $34,000 after buying an additional 1,487 shares during the period. National Bank of Canada FI lifted its holdings in shares of USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after acquiring an additional 1,201 shares during the period. State of Wyoming acquired a new stake in shares of USANA Health Sciences during the 1st quarter worth approximately $57,000. Tower Research Capital LLC TRC boosted its position in shares of USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after acquiring an additional 1,901 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in USANA Health Sciences by 1,354.3% in the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after acquiring an additional 3,589 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

Insider Activity

In other USANA Health Sciences news, insider Brent Neidig sold 5,002 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John Turman Fleming sold 2,450 shares of USANA Health Sciences stock in a transaction on Monday, June 1st. The shares were sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the transaction, the director directly owned 4,230 shares of the company’s stock, valued at $75,843.90. This represents a 36.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 13,869 shares of company stock worth $261,441. Corporate insiders own 0.82% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.